

RHEUMATOLOGY

Dr Irwin Lim
Dr Roberto Russo
Dr Herman Lau
Dr Andrew Jordan
Dr Tim Lu
Dr Nick Benton
Dr Anne Chung

11th September 2014

Dear sir/madam,

Re: Public Consultation on Authority Required Medicines for the Post-market Review of Authority Required PBS Listings

PHYSIOTHERAPY

Errol Lim
Belinda Cheng
Rachael Butterworth
Jean Redmond
Sarah Thamin
Hans Lee

I am a rheumatologist in full time private practice in Sydney.

At this time, I treat around 190 patients with biologic DMARDs. These agents include Etanercept, Adalimumab, Golimumab, Infliximab, Certolizumab, Rituximab and Tocilizumab. For each of these patients, they require at least 2 applications filled each year.

The application process, while understandably rigid and involved, is very time consuming and wasteful.

HAND PHYSIOTHERAPY

Ray Jongs

I agree that we should have to fill in all the paperwork for the following circumstances:

EXERCISE PHYSIOLOGY

Sarah Comensoli
Sharnee Dewstow
Tom Patterson

- a) an initial application
- b) a demonstration of response
- c) a swap in therapy for whatever reason

**DIETETICS & NUTRI-
TION**

Monica Kubizniak
Chloe McLeod
Fiona Kupresanin

However, in the case of a patient who is doing well on therapy, and who will continue on the same therapy, it would be very helpful to move to a streamlined authority listing.

The advantages of this:

- a) Reduced paperwork and savings in time for the rheumatologist
- b) Reduced paperwork and time savings for the PBS employees
- c) Less environmental impact given the reduced paper wastage
- d) Reduced delay in patients receiving their scripts meaning less pain, suffering and frustration. At the moment, given the PBS office in Hobart seems short-staffed, the turnaround time seems to stretch for weeks.

MASSAGE THERAPY

Vanessa Ogata
Hiroko Amagaya
Amanda Fincham

Thank you for your consideration.

Yours sincerely,



Dr Irwin Lim

**RHEUMATOLOGY CARE
COORDINATOR**

Flora Wong

BONE DENSITOMETRY

Dr Irwin Lim
Dr Roberto Russo

